Published in J Immunol on July 25, 2012
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep (2015) 1.18
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med (2014) 1.09
Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology (2013) 0.89
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer (2013) 0.89
Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. Immunology (2014) 0.85
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology (2013) 0.83
ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med (2015) 0.83
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer (2015) 0.83
Considerations for combined immune checkpoint modulation and radiation treatment. Radiat Res (2014) 0.81
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology (2016) 0.81
Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother (2014) 0.78
Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines. Int J Gynecol Cancer (2016) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Animal models for viral infection and cell exhaustion. Curr Opin HIV AIDS (2014) 0.76
Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro. Can J Vet Res (2017) 0.75
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Genome sequence of Azotobacter vinelandii, an obligate aerobe specialized to support diverse anaerobic metabolic processes. J Bacteriol (2009) 1.64
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
(IscS-IscU)2 complex structures provide insights into Fe2S2 biogenesis and transfer. Angew Chem Int Ed Engl (2012) 1.37
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother (2015) 1.35
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One (2012) 1.18
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Cochlin, a secreted von Willebrand factor type a domain-containing factor, is regulated by leukemia inhibitory factor in the uterus at the time of embryo implantation. Endocrinology (2003) 1.17
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol (2011) 1.17
Critical care of the end-stage liver disease patient awaiting liver transplantation. Liver Transpl (2011) 1.15
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother (2011) 1.04
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother (2008) 1.00
Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 0.96
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers (2007) 0.94
The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine (2007) 0.92
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med (2010) 0.92
Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol (2008) 0.91
Nkx2.1 transcription factor in lung cells and a transforming growth factor-beta1 heterozygous mouse model of lung carcinogenesis. Mol Carcinog (2004) 0.89
Jordan palliative care initiative: a WHO Demonstration Project. J Pain Symptom Manage (2007) 0.89
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer (2006) 0.86
Matrilysin-1 mediates bronchiolization of alveoli, a potential premalignant change in lung cancer. Am J Pathol (2009) 0.84
Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer (2006) 0.83
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology (2013) 0.83
Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother (2005) 0.82
B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice. Cell Immunol (2013) 0.82
Ovarian cancer from an immune perspective. Radiat Res (2014) 0.81
Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function. Endocrinology (2008) 0.81
Dok-4 is a novel negative regulator of T cell activation. J Immunol (2009) 0.79
An Emerging Role for PI5P in T Cell Biology. Front Immunol (2013) 0.79
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
Biomarkers of mucinous tumors of the ovary. Dis Markers (2007) 0.78
HPV as a model for the development of prophylactic and therapeutic cancer vaccines. Curr Mol Med (2009) 0.78
Tracheostomy protocol compliance: herding cats? Crit Care Med (2008) 0.77
Relationship of inspiratory flow rate and volume on digit tip skin and ulnar artery vasoconstrictor responses in healthy adults. Microvasc Res (2005) 0.75
Facilitators and Barriers of Heart Surgery Discharge: Patients' and Nurses' Narrative Accounts. J Cardiovasc Nurs (2016) 0.75
Cell cycle and related protein. Dis Markers (2007) 0.75